These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22617225)

  • 1. Models for disease progression: new approaches and uses.
    Mould DR
    Clin Pharmacol Ther; 2012 Jul; 92(1):125-31. PubMed ID: 22617225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seamless phase II/III designs.
    Stallard N; Todd S
    Stat Methods Med Res; 2011 Dec; 20(6):623-34. PubMed ID: 20724313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations in clinical trials of combination antifungal therapy.
    Powers JH
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S228-35. PubMed ID: 15546123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.
    Gieschke R; Reigner BG; Steimer JL
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical modeling of cancer progression and response to chemotherapy.
    Sanga S; Sinek JP; Frieboes HB; Ferrari M; Fruehauf JP; Cristini V
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1361-76. PubMed ID: 17069522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models and approaches for anti-TB drug testing.
    Yasinskaya Y; Sacks L
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment.
    Wierling C; Kühn A; Hache H; Daskalaki A; Maschke-Dutz E; Peycheva S; Li J; Herwig R; Lehrach H
    Mutat Res; 2012 Aug; 746(2):163-70. PubMed ID: 22285941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The virtual laboratory approach to pharmacokinetics: design principles and concepts.
    Huisinga W; Telgmann R; Wulkow M
    Drug Discov Today; 2006 Sep; 11(17-18):800-5. PubMed ID: 16935747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.